Table 2.
Univariate and multivariate analyses for prognostic factors of OS after curative resection for stage I‐III RCC and LCRC
| Factors | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95%CI | P | HR | 95%CI | P | |
| RCC | ||||||
| Age (≥64 vs <64 y) | 1.23 | 0.69‐2.17 | .480 | |||
| Gender (male vs female) | 1.46 | 0.82‐2.61 | .197 | |||
| T stage (T3‐4 vs T1‐2) | 2.85 | 1.02‐7.94 | .045 | 1.61 | 0.55‐4.67 | .382 |
| N stage (N1‐2 vs N0) | 2.17 | 1.22‐3.89 | .009 | 1.98 | 1.09‐3.60 | .024 |
| Differentiation (poor vs others) | 2.21 | 1.25‐3.91 | .007 | 1.93 | 1.07‐3.48 | .029 |
| Lymphovascular invasion | 2.53 | 1.39‐4.58 | .002 | 2.13 | 1.13‐4.02 | .020 |
| Perineural invasion | 1.84 | 0.95‐3.55 | .070 | |||
| No. of lymph node (≥12 vs <12) | 1.16 | 0.56‐2.39 | .693 | |||
| CEA(≥4.25 ng/mL vs <4.25 ng/mL) | 1.95 | 1.09‐3.49 | .024 | 1.99 | 1.07‐3.70 | .030 |
| NLR (≥2.3 vs <2.3) | 2.21 | 1.15‐4.25 | .018 | 2.54 | 1.29‐4.98 | .007 |
| PLR (≥145.2 vs < 145.2) | 2.41 | 1.20‐4.85 | .013 | 2.73 | 1.28‐5.83 | .010 |
| LMR (<3.5 vs ≥3.5) | 2.06 | 1.12‐3.79 | .020 | 2.08 | 1.11‐3.89 | .022 |
| LCRC | ||||||
| Age (≥64 vs <64 y) | 1.42 | 0.86‐2.35 | .172 | |||
| Gender (male vs female) | 1.30 | 0.77‐2.20 | .334 | |||
| T stage (T3‐4 vs T1‐2) | 3.30 | 1.42‐7.67 | .006 | 3.39 | 1.43‐8.04 | .005 |
| N stage (N1‐2 vs N0) | 1.98 | 1.20‐3.28 | .008 | 1.94 | 1.17‐3.23 | .011 |
| Differentiation (poor vs others) | 2.48 | 1.45‐4.24 | .001 | 1.66 | 0.94‐2.92 | .082 |
| Lymphovascular invasion | 3.57 | 2.12‐6.03 | <.001 | 4.04 | 2.31‐7.06 | <.001 |
| Perineural invasion | 1.54 | 0.86‐2.76 | .146 | |||
| No. of lymph node (≥12 vs <12) | 1.60 | 0.89‐2.87 | .117 | |||
| CEA(≥4.25 ng/mL vs <4.25 ng/mL) | 2.01 | 1.20‐3.36 | .008 | 2.59 | 1.51‐4.45 | .001 |
| NLR (≥2.3 vs <2.3) | 1.88 | 1.13‐3.11 | .015 | 1.51 | 0.89‐2.55 | .125 |
| PLR (≥145.2 vs <145.2) | 2.05 | 1.24‐3.39 | .005 | 2.69 | 1.57‐4.62 | <.001 |
| LMR (<3.5 vs ≥3.5) | 1.52 | 0.92‐2.52 | .101 | |||
Abbreviations: 95%CI, 95% confidential interval; CEA, carcinoembryonic antigen; HR, hazard ratio; LMR, lymphocyte‐monocyte ratio; NLR, neutrophil‐lymphocyte ratio; OS, overall survival; PLR, platelet‐lymphocyte ratio; RCRC, right‐sided colon cancer.